These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis.
    Author: Tahamiler R, Saritzali G, Canakcioglu S.
    Journal: Laryngoscope; 2007 Jun; 117(6):965-9. PubMed ID: 17545861.
    Abstract:
    BACKGROUND: Sublingual immunotherapy has a documented clinical efficacy, but only a few long-term studies have been performed in people with perennial rhinitis. OBJECTIVES: The purpose of this study was to evaluate the long-term efficacy of sublingual immunotherapy. METHODS: One hundred thirty-seven patients with allergies to house dust mites were treated with sublingual house dust-mite-specific immunotherapy for 2 or 3 years and were also observed for 3 years after discontinuation of the treatment. The patients were divided into 2 groups: group A (67 patients) received active treatment for 2 years and then 1 year for placebo, and group B (70 patients) received active treatment for 3 years. The success of the treatment was evaluated with the symptom score, skin prick test results, and the nasal allergen challenge score. RESULTS: According to our study results, we found a greater improvement in the 3 years of sublingual immunotherapy compared with the 2 years of sublingual immunotherapy when we looked at the comparative results of the total 6 years. CONCLUSION: We suggest 3 years of sublingual immunotherapy for patients with perennial allergic rhinitis who require immunotherapy and do not accept the subcutaneous route of allergen administration.
    [Abstract] [Full Text] [Related] [New Search]